DiscoverThink Like A Pancreas...The Podcast!The Quest for a Cure: A Diamyd In the Rough
The Quest for a Cure: A Diamyd In the Rough

The Quest for a Cure: A Diamyd In the Rough

Update: 2025-04-22
Share

Description

Episode Summary

In Episode 31 of Think Like a Pancreas-The Podcast, host Gary Scheiner and guest Ginger Vieira discuss the innovative approaches being taken by sponsor, Diamyd Medical in the quest for a cure for type 1 diabetes.


They explore the significance of using precision medicine, and the role of GAD65 therapy to modulate the immune response in the early stages of type one diabetes.


Gary and Ginger share the potential of benefits of Diamyd Medical’s Diagnode-3’s clinical trial, the screening process for participants, and the hope it brings to newly diagnosed individuals.


 


Meet Your Host and His Guest

Gary Scheiner, MS, CDCES, is the award-winning author of Think Like a Pancreas as well as numerous other books that act as guides for people living with diabetes. A Certified Diabetes Educator, Masters-level Exercise Physiologist, and person living with type 1 diabetes since 1985, Gary was named 2014 Diabetes Educator of the Year by the American Association of Diabetes Educators. He trained at the Joslin Diabetes Center and has dedicated his career to helping others live well with diabetes through education, advocacy, and innovation.


Ginger Vieira is a freelance writer, diabetes content specialist, and owner of The Diabetic Nerd. She is passionate about helping people with diabetes and other chronic illnesses live full lives who has lived with type 1 diabetes for 25 years and counting.


What you’ll learn:

  • Recent Vertex results

  • The autoimmune process

  • The importance of precision medicine in treating type 1 diabetes.

  • How GAD65 therapy targets specific antibodies without widespread immune suppression.

  • The process and benefits of participating in clinical trials

  • What is different about Diamyd's Diagnode-3 trial.

  • Who qualifies for the Diagnode-3 trial?

  • What is involved in being a part of Diamyd's clinical trial?

  • How are outcomes measured?

  • What is in it for participants?


Chapters

  • 00:14 – Welcome and Disclaimer

  • 01:00 - Introducing Ginger Vieira

  • 03:09 – Why Ginger is talking about Diamyd

  • 04:00 – Lessons to be learned from Veretex

  • 06:11 - How do you define a cure for type 1 diabetes?

  • 07:33- What is unique about Diamyd's therapy?

  • 08:45 - What is unique about Diamyd's therapy?

  • 11:27 – The importance of pre-diabetes screening

  • 17:19 - The problem of widespread immunosuppression

  • 20:45 - Why should you participate in the Diagnode-3 Clinical Trial?

  • 25:36 - How does Diamyd's clinical trial differ from other trials?

  • 26:56 - Final Thoughts and Future Directions

  • 31:41 - Gary's thoughts on Diamyd Medical's clinical trial


Resources Mentioned:

diabetesnerd.com


https://diagnode-3.com/


Diabetes Research Institute


TrialNet


 


Connect with Us

Subscribe and Review

If you enjoyed this episode subscribe on Apple Podcasts, Spotify, or your favorite podcast platform to ensure that you never miss an episode.


Also, leave a review to let us know what you think, and share this episode with others who will enjoy it as well!


 


Disclaimer


The information contained in this program is based on the experience and opinions of the Integrated Diabetes Services clinical team. Please discuss any changes to your treatment plan with your personal healthcare provider before implementing.


 

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Quest for a Cure: A Diamyd In the Rough

The Quest for a Cure: A Diamyd In the Rough

Integrated Diabetes Services